Ernexa Therapeutics (ERNAW) Stock: Why It's Down Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $0.02, -15.02% vs the prior close of $0.03.
- Volume 9.10K shares, 303.2x its 50-day average (heavy).
- New SEC filings: 8-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
ERNAW slides 15.0% to $0.02 on 303.2x normal volume. Closed at $0.02, -15.02% vs the prior close of $0.03. Day range $0.02–$0.03, opened at $0.03.
ERNAW daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — ERNAW slides 15.0% to $0.02 on 303.2x normal volume
- Closed at $0.02, -15.02% vs the prior close of $0.03. Day range $0.02–$0.03, opened at $0.03.
- Volume was 9.10K shares, 303.2x its 50-day average of 30 — unusually heavy trading.
- 52-week range $0.02–$0.03; today's close sits at 4% of that range, 28.3% below the 52-week high.
ERNAW bull case vs bear case (from the data)
- Insiders made 4 open-market purchases in the last 12 months.
- Share count down 78.7% in a year (buybacks).
- Annual revenue fell 70.7% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: loss of $14.08M.
- High volatility: average daily move of 15.0% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
ERNAW latest news & SEC filings
Every SEC filing by or about ERNAW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 22, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$4.01M (prior year -$3.14M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$3.40 (prior year -$15.19) (loss narrowed vs Jun 30, 2025)
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Jun 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade ERNAW
- Last results release: Mar 20, 2023 (8-K Item 2.02). Previous ones: Apr 15, 2022, Aug 17, 2021, Nov 13, 2020. Based on that rhythm, the next report is likely around Jun 19, 2023 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 15.02% (largest 15.0%). That is a volatile stock.
- Liquidity: about 4.56K shares (≈$98) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.02 vs a range of $0.02–$0.03 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Charles Cherington bought 4,000,000 shares on Feb 10, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Sep 16, 2026; 8-K Sep 16, 2026.
- Share count: 1.63M shares outstanding (Aug 6, 2026), -78.7% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ERNAW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 0.03 | 0.03 | 0.02 | 0.02 | 9.10K |
| Oct 14, 2026 | 0.03 | 0.03 | 0.03 | 0.03 | 30 |
About Ernexa Therapeutics
Ernexa Therapeutics (ERNAW) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 748592.
ERNAW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| James Arthur Bristol | Director | Sep 1, 2026 |
| Peter Cicala | Director | Sep 1, 2026 |
| Sanjeev Luther | President and CEO | Sep 1, 2026 |
| David Polinsky | Director | Sep 1, 2026 |
| Elena Ratner | Director | Sep 1, 2026 |
| Robert J. Spiegel | Director | Sep 22, 2026 |
| William A. Wexler | Director | Sep 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sanjeev Luther | President and CEO | Sep 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 10, 2026 | Charles Cherington | Buy | 4,000,000 | $0.50 |
| Feb 10, 2026 | Charles Cherington | Buy | 4,000,000 | $0.50 |
| Feb 10, 2026 | Charles Cherington | Buy | 4,000,000 | $0.50 |
| Feb 10, 2026 | Charles Cherington | Buy | 4,000,000 | $0.50 |
ERNAW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-14.08M | -2.24 | $-7.02M |
| Dec 31, 2024 | — | $-44.54M | -48.96 | $-15.84M |
| Dec 31, 2023 | — | $-21.67M | -4.08 | $-20.41M |
| Dec 31, 2022 | — | $-24.58M | -8.06 | $-20.98M |
| Dec 31, 2021 | — | $-122.55M | -56.61 | $-23.49M |
Latest balance sheet: total assets $6.32M, total liabilities $3.12M, cash $4.32M (as of Jun 30, 2026).
ERNAW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 20, 2023 | 8-K Item 2.02 (results) | — |
| Apr 15, 2022 | 8-K Item 2.02 (results) | — |
| Aug 17, 2021 | 8-K Item 2.02 (results) | — |
| Nov 13, 2020 | 8-K Item 2.02 (results) | — |
| Aug 7, 2020 | 8-K Item 2.02 (results) | — |
| May 19, 2020 | 8-K Item 2.02 (results) | — |
| Mar 17, 2020 | 8-K Item 2.02 (results) | — |
| Oct 30, 2019 | 8-K Item 2.02 (results) | — |
| Aug 9, 2019 | 8-K Item 2.02 (results) | — |
| May 13, 2019 | 8-K Item 2.02 (results) | — |
| Mar 20, 2019 | 8-K Item 2.02 (results) | — |
| Nov 7, 2018 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Tesla (TSLA)Space Exploration Technologies (SPCX)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on ERNAW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.